Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CBER To Pause Receipt Of Lot Release Samples During Move To White Oak

This article was originally published in The Pink Sheet Daily

Executive Summary

CBER will begin moving to FDA’s main campus about April 25, sooner than initially expected; OGD will relocate about the same time.

You may also be interested in...



The Two Towers: US FDA's HQ Expansion Plans Include Office High-Rises, New Conference Center

Updated master plan for agency's White Oak headquarters is intended to meet needs of up to 18,000 employees.

US FDA Generic Drug Office Director Uhl Announces Retirement

Uhl, who shepherded OGD into the user fee era, will retire in February.

US FDA Generic Drug Office Director Uhl Announces Retirement

Uhl, who shepherded OGD into the user fee era, will retire in February.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS077083

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel